加载中
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
前收盘价
US$22.35
+US$0.14 · +0.63%
盘中时间采用ET。市场数据可能有所延迟。
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
日内区间
当前US$22.35
52周区间
当前US$22.35
盘中时间采用ET。市场数据可能有所延迟。
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
日内区间
当前US$22.35
52周区间
当前US$22.35
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8398万 USD | 5454.9万 USD | 7698.7万 USD | 3862.7万 USD | 2975万 USD |
| 销货成本 | 1885.6万 USD | 2.22亿 USD | 1.89亿 USD | 1.84亿 USD | 1.16亿 USD |
| 毛利 | 6512.4万 USD | −1.67亿 USD | −1.12亿 USD | −1.46亿 USD | −8668.4万 USD |
| 研究与开发 | 3.08亿 USD | 2.22亿 USD | 1.89亿 USD | 1.84亿 USD | 1.16亿 USD |
| 销售、一般及管理费用 | 5274.3万 USD | 4594.4万 USD | 4290.2万 USD | 3799.7万 USD | 3120.2万 USD |
| 营业费用 | 3.51亿 USD | 4594.4万 USD | 4290.2万 USD | 3799.7万 USD | 3120.2万 USD |
| 利息收入 | 2196.9万 USD | 1972.8万 USD | 1111.5万 USD | 350.7万 USD | 82.3万 USD |
| 折旧和摊销 | 1885.6万 USD | 1642.8万 USD | 1365.4万 USD | 1080.8万 USD | 608.2万 USD |
| 营业利润 | −2.86亿 USD | −2.13亿 USD | −1.55亿 USD | −1.84亿 USD | −1.18亿 USD |
| 净利润 | −2.64亿 USD | −1.94亿 USD | −1.44亿 USD | −1.8亿 USD | −1.17亿 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8466.43万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM5623.37万0.07%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4935.47万0.50%98.74亿 USD0.35%US$153.77+3.00%
ARK Genomic Revolution ETFARKG4575.82万2.23%15.57亿 USD0.75%US$51.30+4.08%
Vanguard Extended Market ETFVXF2914.94万0.03%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB1701.46万0.16%108.2亿 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO1515.98万0.11%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO1420.83万0.08%180亿 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
